A 28-week, randomized, double-blind, active-controlled, multicenter study to evaluate the efficacy of subcutaneously administered secukinumab compared to ustekinumab in adult patients with psoriatic arthritis and failure of TNFα-inhibitor treatment (AgAIN)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 12 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Secukinumab (Primary) ; Ustekinumab
Indications Plaque psoriasis; Psoriatic arthritis
Focus Therapeutic Use
Acronyms AgAIN
Sponsors Novartis Pharma

Most Recent Events

09 Aug 2024 Planned primary completion date changed from 31 Jul 2024 to 15 Oct 2024.
09 Feb 2024 Status changed from recruiting to active, no longer recruiting.
13 Dec 2023 Planned primary completion date changed from 15 Dec 2023 to 31 Jul 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight